Charles Wang,
Director & Professor,
Loma Linda University
Dr. Wang, MD, PhD, MPH, is Director of the Center for Genomics and a Professor in the School of Medicine, Loma Linda University (LLU). He had held the positions as Director of the Functional Genomics Core at City of Hope National Medical Center, Associate Professor of Medicine at the David Geffen School of Medicine at UCLA and Director of the Clinical Transcriptional Genomics Core at Cedars-Sinai Medical Center before joining LLU. Dr. Wang is a recipient of several awards, including the AACR-Bristol-Myers Squibb Young Investigator Award of the American Association for Cancer Research and the first place graduate award for Research Excellence of Society of Toxicology. Dr. Wang serves as Editorial Board Members for World Journal of Stem Cells, the Frontiers, and the Single Cell Genomics & Proteomics, the Journal of Clinical and Experimental Genetics, the Aperito Journal of Computer Science and Biology, and Associate Editor for the RNA & Diseases. Dr. Wang is an expert on genomics and transcriptomics, with many high visibility peer-reviewed papers published in the high profile journals such as Nature Biotechnology, Nature Communications and PNAS. He was one of the project leaders for the FDA-led international working group/consortium on MicroArray Quality Control (MAQC) and Sequencing Quality Control (SEQC) projects.
The Concordance of RNA-seq and Microarray is Dependent on Chemical Treatment and Transcript Abundance
Wednesday, 30 September 2015 at 11:30
Add to Calendar ▼2015-09-30 11:30:002015-09-30 12:30:00Europe/LondonThe Concordance of RNA-seq and Microarray is Dependent on Chemical Treatment and Transcript AbundanceNGS, SCA, Mass Spec: The Road to Diagnostics in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Next-generation sequencing technologies have revolutionized the genomic
research and allow the genome and transcriptome of any organism to be
explored without a priori assumptions and with unprecedented throughput.
However, the concordance of RNA-sequencing (RNA-seq) with microarrays
for genome-wide analysis of differential gene expression has not been
rigorously assessed using a range of chemical treatment conditions. Here
we use a comprehensive study design to generate Illumina RNA-seq and
Affymetrix microarray data from the same liver samples of rats exposed
to varying degrees of perturbation by 27 chemicals representing multiple
modes of action (MOAs). The cross-platform concordance in terms of
differentially expressed genes (DEGs) or enriched pathways is linearly
correlated with treatment effect size (R2˜0.8). Furthermore, the
concordance is also affected by transcript abundance and biological
complexity of the MOA. RNA-seq outperforms microarray (93% versus 75%)
in DEG verification as assessed by quantitative RT-PCR, with the gain
mainly due to its improved accuracy for low-abundance transcripts.
Add to Calendar ▼2015-09-28 00:00:002015-09-30 00:00:00Europe/LondonNGS, SCA, Mass Spec: The Road to DiagnosticsNGS, SCA, Mass Spec: The Road to Diagnostics in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-09-30 11:30:002015-09-30 12:30:00Europe/LondonThe Concordance of RNA-seq and Microarray is Dependent on Chemical Treatment and Transcript AbundanceNGS, SCA, Mass Spec: The Road to Diagnostics in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
